BioSpace News Archive

Codagenix Receives FDA Clearance of Investigational New Drug Application for Live-Attenuated, Intranasal RSV Vaccine Candidate CodaVax™-RSV.

Miroculus Partners with Element Biosciences to Validate the Miro Canvas Digital Microfluidics Platform for the AVITI ™ System.

Genomic Testing Cooperative, LCA (GTC) announced that it will be presenting at the American Society of Clinical Oncology (ASCO) 2022 annual meeting data showcasing its new innovative approach to liquid biopsy testing that combines both cell-free-DNA (cfDNA) with cell-free RNA (cfRNA), Liquid Trace™.

According to the National Institutes of Health, aneurysmal subarachnoid hemorrhage has turned into a glaring health burden across the world and possesses high rates of permanent disabilities and fatalities.

Albany NY, United States: According to the report, the global soft tissue market was valued at US$ 4.3 Mn in 2020 and is projected to expand at a CAGR of ~7% from 2021 to 2031.

RELIEF THERAPEUTICS Holding SA announced that, at its Annual General Meeting of shareholders held on Tuesday, May 31, 2022, the proposed resolutions described in the AGM invitation and detailed below were approved by more than 85 percent of the represented votes.

Mainz Biomed N.V. announced that it has successfully completed the conformity assessment of its internal processes to In Vitro Diagnostic Devices Regulation compliance which becomes mandatory from May 26, 2022.

LINDIS Biotech GmbH announces the online publication of an abstract presenting interim data from the Company’s Catunibla Phase I dose escalation trial with CATUMAXOMAB at the American Society of Clinical Oncology Annual Meeting.

The Janssen Pharmaceutical Companies of Johnson & Johnson announced new data from Phase 3 studies demonstrating patients treated with TREMFYA® achieved consistent, long-term efficacy through two years across the domains of active psoriatic arthritis – including joint, skin, enthesitis,a dactylitis,b spinal pain and disease severityc endpoints – irrespective of baseline characteristics.

Neuronascent Inc, announced that the U.S. Food and Drug Administration granted “Orphan Drug Designation” for the company’s NNI-351 treatment of Fragile X Syndrome.